Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7 - PubMed (original) (raw)
Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7
Edwin Bremer et al. Cancer Res. 2005.
Abstract
Current treatment of human T-cell leukemia and lymphoma is predominantly limited to conventional cytotoxic therapy and is associated with limited therapeutic response and significant morbidity. Therefore, more potent and leukemia-specific therapies with favorable toxicity profiles are urgently needed. Here, we report on the construction of a novel therapeutic fusion protein, scFvCD7:sTRAIL, designed to induce target antigen-restricted apoptosis in human T-cell tumors. ScFvCD7:sTRAIL consists of the death-inducing tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) genetically linked to an scFv antibody fragment specific for the T-cell surface antigen CD7. Treatment with scFvCD7:sTRAIL induced potent CD7-restricted apoptosis in a series of malignant T-cell lines, whereas normal resting leukocytes, activated T cells, and vascular endothelial cells (human umbilical vein endothelial cells) showed no detectable apoptosis. The apoptosis-inducing activity of scFvCD7:sTRAIL was stronger than that of the immunotoxin scFvCD7:ETA. In mixed culture experiments with CD7-positive and CD7-negative tumor cells, scFvCD7:sTRAIL induced very potent bystander apoptosis of CD7-negative tumor cells. In vitro treatment of blood cells freshly derived from T-acute lymphoblastic leukemia patients resulted in marked apoptosis of the malignant T cells that was strongly augmented by vincristin. In conclusion, scFvCD7:sTRAIL is a novel recombinant protein causing restricted apoptosis in human leukemic T cells with low toxicity for normal human blood and endothelial cells.
Similar articles
- Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative.
Wajant H, Moosmayer D, Wüest T, Bartke T, Gerlach E, Schönherr U, Peters N, Scheurich P, Pfizenmaier K. Wajant H, et al. Oncogene. 2001 Jul 5;20(30):4101-6. doi: 10.1038/sj.onc.1204558. Oncogene. 2001. PMID: 11494138 - CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia.
Bremer E, ten Cate B, Samplonius DF, de Leij LF, Helfrich W. Bremer E, et al. Blood. 2006 Apr 1;107(7):2863-70. doi: 10.1182/blood-2005-07-2929. Epub 2005 Dec 6. Blood. 2006. PMID: 16332967 - Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
Brinkmann U. Brinkmann U. In Vivo. 2000 Jan-Feb;14(1):21-7. In Vivo. 2000. PMID: 10757057 Review. - CD7-specific single chain Fv immunotoxins. Design and expression.
Pennell CA, Pauza ME. Pennell CA, et al. Methods Mol Biol. 2001;166:17-29. doi: 10.1385/1-59259-114-0:17. Methods Mol Biol. 2001. PMID: 11217366 Review. No abstract available.
Cited by
- Targeted delivery of tumor necrosis factor-related apoptosis-inducing ligand to keratinocytes with a pemphigus mAb.
Kouno M, Lin C, Schechter NM, Siegel D, Yang X, Seykora JT, Stanley JR. Kouno M, et al. J Invest Dermatol. 2013 Sep;133(9):2212-20. doi: 10.1038/jid.2013.85. Epub 2013 Feb 25. J Invest Dermatol. 2013. PMID: 23439393 Free PMC article. - The promise of TRAIL--potential and risks of a novel anticancer therapy.
Koschny R, Walczak H, Ganten TM. Koschny R, et al. J Mol Med (Berl). 2007 Sep;85(9):923-35. doi: 10.1007/s00109-007-0194-1. Epub 2007 Apr 17. J Mol Med (Berl). 2007. PMID: 17437073 Review. - CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells.
El-Mesery M, Trebing J, Schäfer V, Weisenberger D, Siegmund D, Wajant H. El-Mesery M, et al. Cell Death Dis. 2013 Nov 14;4(11):e916. doi: 10.1038/cddis.2013.402. Cell Death Dis. 2013. PMID: 24232092 Free PMC article. - Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells.
Tang J, Li J, Zhu X, Yu Y, Chen D, Yuan L, Gu Z, Zhang X, Qi L, Gong Z, Jiang P, Yu J, Meng H, An G, Zheng H, Yang L. Tang J, et al. Oncotarget. 2016 Jun 7;7(23):34070-83. doi: 10.18632/oncotarget.8710. Oncotarget. 2016. PMID: 27083001 Free PMC article. - Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane.
Su Y, Tatzel K, Wang X, Belt B, Binder P, Kuroki L, Powell MA, Mutch DG, Hawkins WG, Spitzer D. Su Y, et al. Oncotarget. 2016 May 24;7(21):31534-49. doi: 10.18632/oncotarget.8925. Oncotarget. 2016. PMID: 27120790 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources